Superficial Nonpurulent Earlobe Cellulitis
Cellulitis confined to the earlobe with preserved cartilage should be managed as mild, nonpurulent skin infection if no abscess and no systemic toxicity are present. Outpatient oral therapy is recommended for patients without SIRS, altered mental status, or hemodynamic instability (strong, moderate). [1]
Initial Assessment and Exclusion of Deeper Infection
Cartilage involvement or deeper infection should be excluded because hospitalization and broader evaluation are indicated when deeper or necrotizing infection is suspected. Hospitalization is recommended for concern for a deeper or necrotizing infection, poor adherence to therapy, severe immunocompromise, or outpatient failure (moderate or severe nonpurulent; strong, moderate). [1]
Medication Selection Algorithm
Empiric therapy for nonpurulent cellulitis should include an antibiotic active against streptococci. [1]
Empiric streptococcal-focused oral options (typical cellulitis): [1]
- Penicillin (for streptococcal skin infection) [1]
- Amoxicillin [1]
- Penicillin VK [1]
- Cephalexin [1]
- Dicloxacillin [1]
- Clindamycin [1]
MSSA coverage is commonly added when staphylococcal infection is suspected. [1]
Monotherapy Versus Combination Therapy
Monotherapy with a streptococcal-active beta-lactam (eg, penicillin, amoxicillin, or cephalexin) is an appropriate approach for typical nonpurulent cellulitis without MRSA risk factors. [1]
Combined therapy to include MRSA is reserved for circumstances such as penetrating trauma, MRSA elsewhere, nasal MRSA colonization, injection drug use, purulent drainage, or severe nonpurulent infection meeting SIRS criteria (strong, moderate). [1]
Treatment Initiation Thresholds
Outpatient oral therapy is appropriate when all of the following are absent: [1]
- SIRS [1]
- Altered mental status [1]
- Hemodynamic instability [1]
Systemic antibiotics are indicated for moderate nonpurulent cellulitis with systemic signs of infection. [1]
Target and Duration of Therapy
The recommended duration of antimicrobial therapy for cellulitis is 5 days. [1]
Treatment should be extended if the infection has not improved within 5 days. [1]
Common Pitfalls to Avoid
Failure to recognize progression risk should be avoided because hospitalization is recommended when concern exists for deeper or necrotizing infection, severe immunocompromise, poor adherence, or outpatient failure (moderate or severe nonpurulent; strong, moderate). [1]
Inadequate MRSA coverage should be avoided when MRSA risk factors or severe nonpurulent/SIRS criteria are present, because MRSA-active therapy is recommended in those settings (strong, moderate). [1]
Goals of Therapy and Supportive Measures
Elevation of the affected area and treatment of predisposing factors such as edema or underlying cutaneous disorders are recommended (strong, moderate). [1]
Marking the clinical border to document response and arranging short-interval reassessment is recommended as a general cellulitis management strategy. [2]